# FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC

> **NCT07729605** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 270 (estimated)

## Conditions studied

- Colorectal Cancer Metastatic
- Microsatellite Stable (MSS) Colorectal Cancer (CRC)

## Interventions

- **DRUG:** FOLFIRI + bevacizumab + QL1706
- **DRUG:** FOLFIRI + bevacizumab

## Key facts

- **NCT ID:** NCT07729605
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-30
- **Primary completion:** 2028-12-30
- **Final completion:** 2029-07-30
- **Target enrollment:** 270 (ESTIMATED)
- **Last updated:** 2026-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07729605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07729605, "FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07729605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*